AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 112 min read$ICLR

Balfe Barry Edward sold $63K of ICLR

Balfe Barry Edward (Chief Executive Officer) sold 382 shares of ICON PLC (ICLR) at an average of $164.07 ($163.80–$165.14) across 2 trades on 2026-08-10.

Original reporting
SEC EDGAR · Balfe Barry Edward
Published Aug 11, 2026, 8:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ICLR
Neutral
medium confidence
Mentioned
$ICLR
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICLRNeutralLow
01

Why it matters

The only new fact is the CEO’s Aug 10 open-market sale details and resulting holdings; there is no accompanying guidance, deal, or regulatory development.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not change ICON PLC fundamentals.

03

What to watch

The article does not state motivations, tax planning, or whether other sales occurred; it also shows a relatively small share count versus typical institutional trading flows.

Relevance 3/10Novelty 3/10Timing: filed after-hours on Aug 11, covering Aug 10 sale

Background

The article is a SEC Form 4 insider transaction disclosure for ICON PLC (ICLR) by its CEO.

Company-level read

Ticker impact

$ICLRNeutralMedium confidence
Context

ICON PLC CEO Balfe Barry Edward sold 382 shares in open-market trades at about $164.07 weighted average, per Form 4 filed Aug 11.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing discloses the transaction size, price range, and post-sale holdings, but provides no new operational, financial, or regulatory information about ICON PLC.

Market effects

Sector

No clear sector read-through from a single CEO open-market sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be routine liquidity events, so the market may overreact to the absence of a stated 10b5-1 plan.

Key entities

  • issuer
    ICON PLC

    Company whose CEO insider sale is disclosed in the Form 4.

  • insider
    Balfe Barry Edward

    ICON PLC CEO and reporting person who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ICLR insider trading history →

Related articles

JUL 29
$ICLRMedAI 9/10

ICON plc: ICON Reports Second Quarter 2026 Results

ICON plc (NASDAQ: ICLR) reported Q2 2026 results. Revenue was $2,063.5 million, up 1.4% QoQ. Adjusted EBITDA was $327.2 million (15.9% of revenue). GAAP net income was $72.6 million ($0.94 diluted EPS) and adjusted net income was $198.4 million ($2.56 adjusted EPS). Net business wins were $3,120 million, backlog $23.4 billion, and it reaffirmed 2026 guidance.

finanznachrichten.de3 min
JUL 29
$ICLRHighAI 8/10

ICON PLC (ICLR): Financial results for Q2 2026

ICON PLC (ICLR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ICON Reports Second Quarter 2026 Results Highlights • Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. • Quarter two adjusted EBITDA of $327.2 million or 15.9% of revenue, an increase of 3.0% on quarter one 2026. • GAAP net income for

SEC EDGAR 6-K2 min
JUL 28
$ICLRMed

ICON stock surges 7% on Anthropic AI partnership for trials By Investing.com

ICON plc (NASDAQ:ICLR) shares rose about 7.8% after the company announced a multi-year partnership with Anthropic to integrate Claude AI into its Orbis clinical trial platform. ICON said the collaboration will add four production capabilities, including site intelligence and enrollment risk detection, and will roll out Claude across roles. ICON cited enrollment delays affecting up to 80% of trials.

investing.com3 min
JUL 28
$ICLRMed

ICON, Anthropic Sign Multi-Year Partnership Deal To Advance AI Capabilities, Stock Up In Pre-Market

ICON Public Limited Company (ICLR) said it signed a multi-year partnership with Anthropic to integrate Claude AI across the clinical trial lifecycle using ICON’s Orbis platform. ICON plans to work with Anthropic’s life sciences team and deploy Claude Code, Claude, and Claude Science. The company cited CEO Barry Balfe. In pre-market, ICLR rose to $177.69, up 5.28% on Nasdaq.

rttnews.com2 min